Description
Anaplastic lymphoma kinase (ALK) known as ALK tyrosine kinase receptor or CD246, is a tyrosine kinase receptor. ALK is an important biomarker for diagnosis of non-small cell lung cancer (NSCLC). Zykadia (Ceritinib) has been permitted for treating patent with ALK-Positive NSCLC.